Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
150 participants
OBSERVATIONAL
2021-06-01
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stomach Cancer Exosome-based Detection
NCT06342427
Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1
NCT05647941
Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT
NCT06716593
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
NCT06940102
A Web-based Calculator Predicts Heterogeneous Frailty Trajectories
NCT05982899
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gastric cancer patients with non-cachexia
cachexia
Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
Gastric cancer patients with cachexia
cachexia
Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cachexia
Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Complete clinical and pathological data
3. No previous or current mental illness or disturbance of consciousness
Exclusion Criteria
2. Combined with other chronic wasting and metabolic diseases
3. Past patients with non-tumor cachexia
4. People with mental illness or unable to cooperate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xijing Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fourth Military Medical University
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jipeng Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20212018-F-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.